Imatinib CAS 152459-95-5 Raw Materials Powder

CAS: 152459-95-5

MF: C29H31N7O

Specification​: 99% min Imatinib Powder

Sample: Imatinib Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https:https://henrikang.en.made-in-china.com/

Imatinib Powder Usage and Synthesis .

Imatinib is an oral anticancer drug used to treat chronic myeloid leukemia and lung cancer. It is a tyrosine kinase inhibitor that slows the progression of cancer by blocking the proliferation and spread of cancer cells.

The main component of imatinib is imatinib slow-release, which inhibits the BCR-ABL fusion protein in cancer cells, a major causative factor in chronic myeloid leukemia. The mechanism of action of imatinib is to block the proliferation and spread of cancer cells by inhibiting the tyrosine kinase activity of the BCR-ABL fusion protein.

The usage and dosage of Imatinib needs to be determined according to the patient's condition and the doctor's recommendation. In general, patients with chronic myeloid leukemia are given 400 mg of Imatinib orally daily and patients with lung cancer are given 250 mg of Imatinib orally daily. The length of the course of treatment also depends on the patient's condition and generally requires long-term administration.

Application/Function of Imatinib Powder .

Imatinib has been shown to have significant efficacy in the treatment of cancer. In the treatment of chronic myeloid leukemia, Imatinib can achieve complete or partial remission in approximately 80% of patients. In the treatment of lung cancer, imatinib can prolong patients' survival and relieve symptoms.

Imatinib also has some side effects, including nausea, vomiting, diarrhea, fatigue, headache, and fever. While using Imatinib, patients need to keep a close eye on their health and report any discomfort to their doctor in a timely manner.

Overall, Imatinib is an effective anti-cancer drug with remarkable efficacy in the treatment of chronic myeloid leukemia and lung cancer. Patients need to pay close attention to their health conditions while using Imatinib and follow their doctor's recommendations for treatment.

Oral drug for the treatment of adult patients with Philadelphia chromosome (Ber-Abl) positive chronic myeloid leukemia in the acute phase, accelerated phase, and chronic phase after failure of interferon therapy

Production method of Imatinib Powder .

Imatinib is an oral drug used to treat the acute, accelerated, and chronic phases after failure of interferon therapy in adult patients with Philadelphia chromosome (Ber-Abl) positive chronic myeloid leukemia (CML), a hematopoietic stem cell disorder caused by abnormalities in the DNA of stem cells in the bone marrow.

CML is divided into three phases: chronic phase, accelerated phase and critical phase, with the average survival elbow time for patients in the critical phase being only 2-3 months. Imatinib is also effective in the treatment of gastrointestinal mesenchymal tumors, with an efficiency rate of about 50%.

Imatinib is a novel 2-anilino-pyrimidine tyrosine kinase inhibitor. It can effectively inhibit the activity of Bcr-abl tyrosine kinase at the cellular level, which is the product of abnormal expression of Ph chromosome in chronic granulocytic leukemia (CML), so imatinib can selectively inhibit the proliferation and induce apoptosis of cells of Ber-abl positive cell lines and cells of chronic granulocytic leukemia patients.

In addition, imatinib inhibits platelet-derived growth factor (PDGF) receptor, stem cell factor (SCF), and tyrosine kinase of c-Kit receptor, thereby suppressing cellular behaviors mediated by PDGF and stem cell factor, but does not affect the signaling of other stimulatory factors, such as epidermal growth factor.